LMC Healthcare’s Post

Despite innovation in treatments for Type 2 diabetes, patients still struggle to access holistic advice and face inconsistent and inefficient care. In our new whitepaper, our experts outline how the industry can overcome clinical inertia and confusion, drive adoption, and meet unmet patient needs: https://bit.ly/3yoVcOC #WeAreAvalereHealth #GLP1 #Diabetes

Despite innovation in treatments for Type 2 diabetes, patients still struggle to access holistic advice and face inconsistent and inefficient care. In our new whitepaper, our experts outline how the industry can overcome clinical inertia and confusion, drive adoption, and meet unmet patient needs: https://bit.ly/3yoVcOC #WeAreAvalereHealth #GLP1 #Diabetes

Learn how to apply strategies using the Global Initiative for Asthma and CTS recommendations to effectively assess, intervene, and partner with patients and their healthcare providers to improve asthma care: https://ow.ly/bRHe50QCOh0

Learn how to apply strategies using the Global Initiative for Asthma and CTS recommendations to effectively assess, intervene, and partner with patients and their healthcare providers to improve asthma care: https://ow.ly/bRHe50QCOh0

Prescribing costs are analysed by NHS managers in isolation of associated healthcare costs. So GPs are incentivised to prescribe cheaply. In asthma where short acting beta-2- bronchodilators (SABAs) are prescribed in excess, and at risk for patients, the costs increase exponentially with increased numbers of these SABAs per year. We analysed the costs in two published papers and present them in an easy to understand infographic- hopefully health care managers will now actively discourage excess SABAs and favour Inhaled Corticosteroids for all people with asthma - either as needed with formoterol or as part of a MART regime as per www.ginasthma.org. Asthma: effect of excess short-acting β2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation https://lnkd.in/eZ6cAPsj

📢 Join the EUFOREA Patient Advisory Board! If you are a patient with Chronic Rhinosinusitis (with or without nasal polyps), #asthma, or allergic rhinitis (hay fever), and would like to learn more about how you can contribute to improving patient care, then this initiative is for you! Participate here: https://lnkd.in/emY-EMPb At EUFOREA, we believe that #patient voices play a critical role in the advancement of care for patients living with: 👉 Chronic Rhinosinusitis (with or without #nasalpolyps) 👉 Asthma 👉 Allergic Rhinitis Since its launch in 2017, the EUFOREA Patient Advisory Board has acted as a platform where patients can discuss the physical, emotional, and financial implications of their condition, as well as its impact on their quality of life. Within the patient advisory board, participants share their unmet needs, propose improvements in care, and suggest ways to increase awareness at a political level. This involves deliberating on solutions for timely and affordable access to cutting-edge treatments. #euforea #patientadvisoryboard #advisoryboard #patientcare #patients #chronicdiseases #patientvoices #treatments #health #healthcare #patientawareness #ngo

During winter, hospital admissions for respiratory disease double across England.    Patients who suffer from Chronic Obstructive Pulmonary Disease, COPD, often have poor self-management and consequently have more frequent interactions with the healthcare system.  Effective self-management is key to reducing hospital admissions 🔑 See how we enabled a 30% reduction in appointment demand for practices: https://lnkd.in/ewGPauEw  #generalpractice #COPD #respiratoryhealth

Revolutionizing Diabetes Care: Artificial Pancreas Technology Offered to Patients in England   Tens of thousands of people in the UK with type 1 diabetes are to be given a new technology called an artificial pancreas to help treat the disease.   This system uses a subcutaneous glucose sensor to automatically calculate the amount of insulin delivered through the pump.   Later this month, the NHS will start contacting adults and children who may benefit from the system.   But NHS chiefs have warned that it could be five years before everyone eligible has the chance to get insurance.   #DiabetesTechnology #ArtificialPancreas #Type1Diabetes #NHS #HealthcareInnovation #DiabetesManagement #MedicalAdvancements #HealthTech #ChronicIllness #PublicHealth #NICE #BloodGlucoseControl #QualityOfLife #PatientCare #MedicalBreakthrough #DiabetesAwareness #HealthEquity #InnovativeHealthcare #UKHealthcare #MedicalResearch  

How to manage diabetes in the common setting of CKD: we're highlighting this guideline summary from the PcMED Project, our sister site for primary care https://lnkd.in/e9VnfkAs #diabetes #kidneydisease #medicine #primarycare

Patients with Type 2 diabetes are facing roadblocks to access and benefit from innovative therapies, as key areas of unmet need prevent patients from receiving optimal care. Avalere Health’s experts analyze the clinical bottlenecks that face people with diabetes, and give six recommendations on how the industry can support patients in our new whitepaper: https://bit.ly/3yoVcOC #WeAreAvalereHealth #GLP1 #Diabetes